$VYGR
Voyager Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000155837023008656 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $4.853M $150.5M
YoY Change 581.6% 22769.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.294M $9.028M
YoY Change 9.83% 17.87%
% of Gross Profit
Research & Development $21.99M $18.57M
YoY Change 75.5% 29.4%
% of Gross Profit
Depreciation & Amortization $1.086M $1.075M
YoY Change -9.8% -61.77%
% of Gross Profit
Operating Expenses $30.28M $27.60M
YoY Change 50.8% 25.39%
Operating Profit -$25.43M $122.9M
YoY Change 31.29% -675.57%
Interest Expense $3.274M $1.864M
YoY Change 1394.98% 5912.9%
% of Operating Profit 1.52%
Other Income/Expense, Net $3.000K $1.864M
YoY Change -98.93% 5912.9%
Pretax Income -$22.15M $124.7M
YoY Change 16.04% -685.15%
Income Tax $59.00K $704.0K
% Of Pretax Income 0.56%
Net Earnings -$22.21M $124.0M
YoY Change 16.35% -681.85%
Net Earnings / Revenue -457.61% 82.43%
Basic Earnings Per Share -$0.51 $3.05
Diluted Earnings Per Share -$0.51 $2.94
COMMON SHARES
Basic Shares Outstanding 43.54M 43.29M
Diluted Shares Outstanding 43.52M 42.16M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $272.7M $273.3M
YoY Change 84.22% 63.82%
Cash & Equivalents $244.3M $268.3M
Short-Term Investments $28.45M $4.993M
Other Short-Term Assets $6.080M $3.983M
YoY Change 77.73% 10.27%
Inventory
Prepaid Expenses
Receivables $3.350M $25.33M
Other Receivables $0.00 $0.00
Total Short-Term Assets $282.2M $302.6M
YoY Change 86.1% 77.34%
LONG-TERM ASSETS
Property, Plant & Equipment $31.77M $17.14M
YoY Change 66.57% -11.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.593M $1.515M
YoY Change 5.15% -14.84%
Total Long-Term Assets $33.36M $33.67M
YoY Change -9.78% -37.1%
TOTAL ASSETS
Total Short-Term Assets $282.2M $302.6M
Total Long-Term Assets $33.36M $33.67M
Total Assets $315.5M $336.3M
YoY Change 67.3% 50.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.659M $3.698M
YoY Change 36.21% 208.17%
Accrued Expenses $12.07M $7.639M
YoY Change 68.03% -1.24%
Deferred Revenue $31.67M $5.680M
YoY Change -63.6% -93.47%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $45.40M $19.94M
YoY Change -53.64% -80.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $71.11M $20.52M
YoY Change 212.7% -46.17%
Total Long-Term Liabilities $71.11M $20.52M
YoY Change 212.7% -46.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $45.40M $19.94M
Total Long-Term Liabilities $71.11M $20.52M
Total Liabilities $116.5M $119.3M
YoY Change -9.37% -19.51%
SHAREHOLDERS EQUITY
Retained Earnings -$291.7M -$269.5M
YoY Change -24.72% -26.85%
Common Stock $44.00K $43.00K
YoY Change 15.79% 13.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $199.0M $217.0M
YoY Change
Total Liabilities & Shareholders Equity $315.5M $336.3M
YoY Change 67.3% 50.01%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$22.21M $124.0M
YoY Change 16.35% -681.85%
Depreciation, Depletion And Amortization $1.086M $1.075M
YoY Change -9.8% -61.77%
Cash From Operating Activities -$835.0K $123.6M
YoY Change -95.48% 258.93%
INVESTING ACTIVITIES
Capital Expenditures $1.210M $509.0K
YoY Change -197.42% 1239.47%
Acquisitions
YoY Change
Other Investing Activities -$23.45M $15.00M
YoY Change -32.78% -175.15%
Cash From Investing Activities -$24.66M $14.49M
YoY Change -31.74% -172.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.548M 31.31M
YoY Change 91.82% 260783.33%
NET CHANGE
Cash From Operating Activities -835.0K 123.6M
Cash From Investing Activities -24.66M 14.49M
Cash From Financing Activities 1.548M 31.31M
Net Change In Cash -23.95M 169.4M
YoY Change -55.49% 1072.87%
FREE CASH FLOW
Cash From Operating Activities -$835.0K $123.6M
Capital Expenditures $1.210M $509.0K
Free Cash Flow -$2.045M $123.1M
YoY Change -88.14% 257.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Operating Lease Income Comprehensive Income Extensible List
OperatingLeaseIncomeComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2022#OperatingExpenses
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38613891
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43435889
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37625
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Voyager Therapeutics, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3003182
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
64 Sidney Street
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2023Q1 dei City Area Code
CityAreaCode
857
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
259-5340
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
VYGR
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43535599
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
268321000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98959000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
4993000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19889000
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
25000000
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
328000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
257000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3983000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5394000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
302625000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
124499000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17138000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17857000
CY2023Q1 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1515000
CY2022Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1515000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15016000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15485000
CY2023Q1 us-gaap Assets
Assets
336294000
CY2022Q4 us-gaap Assets
Assets
159356000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3698000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2566000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7639000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7816000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2922000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2832000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5680000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
59377000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19939000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
72591000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
78872000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6450000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20522000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21295000
CY2023Q1 us-gaap Liabilities
Liabilities
119333000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2558000
CY2022Q4 us-gaap Liabilities
Liabilities
100336000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2022Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Restricted Cash Asset Statement Of Financial Position Extensible List
RestrictedCashAssetStatementOfFinancialPositionExtensibleList
http://www.voyagertherapeutics.com/20230331#DepositsAndOtherNonCurrentAssets
CY2023Q1 us-gaap Restricted Cash Asset Statement Of Financial Position Extensible List
RestrictedCashAssetStatementOfFinancialPositionExtensibleList
http://www.voyagertherapeutics.com/20230331#DepositsAndOtherNonCurrentAssets
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001640266
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2023Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43435889
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38613891
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
43000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
486518000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
452713000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-132000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-219000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-269468000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-393512000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216961000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
59020000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
336294000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159356000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
150480000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
658000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18568000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14349000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9028000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7659000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
27596000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
22008000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
122884000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21350000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1864000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
31000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1864000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
31000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
124748000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21319000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
704000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
124044000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21319000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
87000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-85000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
87000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-85000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
124131000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21404000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.05
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.94
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40632087
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38049430
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42161326
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38049430
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95055000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2268000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-85000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21319000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
75931000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
59020000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
185000
CY2023Q1 vygr Stock Issued During Period Value Collaboration Agreement
StockIssuedDuringPeriodValueCollaborationAgreement
31121000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2504000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
87000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
124044000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216961000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
124044000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-21319000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2558000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2319000
CY2023Q1 us-gaap Depreciation
Depreciation
1075000
CY2022Q1 us-gaap Depreciation
Depreciation
2812000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
17000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-21000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-44000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
25000000
CY2023Q1 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
71000
CY2022Q1 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-526000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1411000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
185000
CY2023Q1 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-469000
CY2022Q1 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-1080000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1132000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
626000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-122000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3494000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-683000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1307000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
18725000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
53347000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
123565000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
34426000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
509000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
19960000
CY2023Q1 vygr Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
15000000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14491000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19998000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
185000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
12000
CY2023Q1 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
31121000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31306000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
169362000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14440000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100474000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119212000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
269836000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
133652000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
109000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
228000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">VOYAGER THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE</b><b style="font-weight:bold;">S TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Voyager Therapeutics, Inc. (the “Company”) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The Company focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines, with the goal of either halting or slowing disease progression or reducing symptom severity, therefore providing clinically meaningful impact to patients. The Company’s gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (“AAV”) based gene therapies that it believes have the potential to safely provide durable efficacy. The Company’s team of experts in the field of AAV gene therapy and neuroscience first identifies and selects diseases in which the Company believes an AAV gene therapy or other biological therapy will answer a high unmet medical need, be supported by target validation, offer an efficient path to human proof of biology, present robust preclinical pharmacology, and offer strong commercial potential. The Company then engineers and optimizes an AAV vector or other biological therapy for activity in, efficacy in, or delivery to, the targeted tissue or cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is identifying proprietary AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. The Company’s team has developed a proprietary AAV capsid discovery platform called TRACER<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood-brain barrier (“BBB”). The TRACER discovery platform is a broadly applicable, functional RNA-based AAV capsid discovery platform that allows for rapid <i style="font-style:italic;">in vivo</i> evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates. The Company believes that the capsids it discovers through its TRACER discovery platform (“TRACER Capsids”) have the potential to significantly enhance the efficacy and safety of its single dose gene therapies, which it expects to be delivered with systemic infusions, as compared with conventional capsids.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to leveraging TRACER capsids in potential licensing arrangements, the Company is advancing its own proprietary pipeline of drug candidates for neurological diseases. The Company’s wholly-owned prioritized pipeline programs include: superoxide dismutase 1 (“SOD1”) gene therapy for amyotrophic lateral sclerosis (“ALS”) and an anti-tau antibody for Alzheimer’s disease. The Company has identified a lead development candidate in its anti-tau antibody program in the first quarter of 2023 and expects to submit an investigational new drug application (“IND”) to the U.S. Food and Drug Administration (“FDA”) in the first half of 2024. The Company previously announced that it expected to identify a lead development candidate for its SOD1 program in the first half of 2023. The Company continues to evaluate the data from preclinical studies for this program and now expects to identify a lead development candidate in the second half of 2023. The Company intends to provide updated guidance on IND timeline once it selects the development candidate. Given where the Company is today, the Company expects the IND to occur in mid-2025. In addition to these two wholly-owned programs, the Company is actively advancing two programs in collaboration with Neurocrine Biosciences, Inc. (“Neurocrine”): a glucocerebrosidase 1 (“GBA1”) gene therapy program for Parkinson’s disease and other GBA1-mediated diseases, and a FXN gene therapy program for Friedreich’s ataxia. The Company also maintains a robust early research pipeline of wholly-owned and collaborative gene therapy programs for neurological diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring annual net operating losses. As of March 31, 2023, the Company had an accumulated deficit of $269.5 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities and funding from fees, milestone payments, and cost reimbursements associated with its prior collaborations with Sanofi Genzyme Corporation (“Sanofi Genzyme”) and AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company, its ongoing collaborations with Neurocrine, its option and license agreement with Pfizer Inc. (“Pfizer”), and its option and license agreement with Novartis Pharma AG (“Novartis”)<span style="font-family:'Times';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of March 31, 2023, the Company had cash, cash equivalents, and marketable securities of $273.3 million. Based upon its current operating plan, the Company expects that its existing cash, cash equivalents, and marketable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">securities at March 31, 2023, together with the<span style="background:#ffffff;"> </span><span style="background:#ffffff;">$25.0</span><span style="background:#ffffff;"> million option exercise payment received in April 2023 from Novartis, a</span>long with amounts expected to be received as reimbursement for development costs under the Company’s collaboration and license agreements with Neurocrine, will be sufficient to meet the Company’s planned operating expenses and capital expenditure requirements into 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition. </p>
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-269500000
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
273300000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</p>
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2319000
CY2023Q1 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
265722000
CY2023Q1 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
4000
CY2023Q1 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
265718000
CY2022Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
111704000
CY2022Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
91000
CY2022Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
111613000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
5000000.0
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
19900000
CY2023Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
268321000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131873000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1515000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
1779000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
269836000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
133652000
CY2023Q1 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3205000
CY2022Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
1895000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2490000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4559000
CY2023Q1 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
1055000
CY2022Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
636000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
889000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
726000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7639000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7816000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M18D
CY2023Q1 vygr Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.074
CY2022Q1 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
690000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2922000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2832000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2922000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2832000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19521000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20294000
CY2023Q1 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2022Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20522000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21295000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2558000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2319000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6199571
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.12
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6095000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1358200
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.55
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
51993
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.56
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
145033
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.42
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7360745
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.10
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10631000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3133247
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.28
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4025000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8741904
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8060362
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
124044000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21319000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40632087
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38049430
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40632087
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38049430
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1529239
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42161326
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38049430

Files In Submission

Name View Source Status
vygr-20230331_def.xml Edgar Link unprocessable
vygr-20230331_cal.xml Edgar Link unprocessable
0001558370-23-008656-index-headers.html Edgar Link pending
0001558370-23-008656-index.html Edgar Link pending
0001558370-23-008656.txt Edgar Link pending
0001558370-23-008656-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vygr-20230331.xsd Edgar Link pending
vygr-20230331x10q.htm Edgar Link pending
vygr-20230331x10q006.jpg Edgar Link pending
vygr-20230331xex10d5.htm Edgar Link pending
vygr-20230331xex31d1.htm Edgar Link pending
vygr-20230331xex31d2.htm Edgar Link pending
vygr-20230331xex32d1.htm Edgar Link pending
vygr-20230331_lab.xml Edgar Link unprocessable
vygr-20230331x10q_htm.xml Edgar Link completed
vygr-20230331_pre.xml Edgar Link unprocessable